Merck KGaA paid Ablynx EUR 20M upfront plus up to EUR 10.7M in research funding and up to EUR 1.7B in development, regulatory and commercial milestones across five Nanobody programs targeting immune checkpoint modulators. The deal vaulted Merck KGaA into the immuno-oncology platform race and was later expanded by an additional EUR 4B in 2015.